COMMUNIQUÉS West-GlobeNewswire
-
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
20/09/2024 - 13:30 -
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma
20/09/2024 - 13:40 -
Communiqué de presse : Le CHMP recommande l’approbation du Dupixent dans l’UE pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois
20/09/2024 - 13:45 -
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
20/09/2024 - 13:45 -
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
20/09/2024 - 13:45 -
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™
20/09/2024 - 14:00 -
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
20/09/2024 - 14:10 -
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
20/09/2024 - 14:30 -
Autonomix Selected to Present at the 2024 Octane Medical Innovation Forum
20/09/2024 - 14:30 -
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
20/09/2024 - 14:30 -
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
20/09/2024 - 14:43 -
Le médicament Iqirvo® (élafibranor) d’Ipsen est approuvé dans l’Union européenne comme premier nouveau traitement contre la cholangite biliaire primitive depuis près d’une décennie
20/09/2024 - 14:57 -
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
20/09/2024 - 14:57 -
Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
20/09/2024 - 15:00 -
BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets
20/09/2024 - 15:00 -
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
20/09/2024 - 15:00 -
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
20/09/2024 - 15:00 -
MESMERIZE brings community pharmacy leaders together to explore industry’s bright future
20/09/2024 - 15:00 -
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
20/09/2024 - 15:01
Pages